Prophylactic Ivermectin in COVID 19 Contacts
Phase 3
- Registration Number
- CTRI/2020/08/027282
- Lead Sponsor
- Department of Community Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All the family members of a newly diagnosed Covid-19 patient who are - living with the patient in the last 2 weeks, aged between 18 years and 60 years of age, asymptomatic on the day of diagnosis of the index case.
Exclusion Criteria
The following will be excluded from the study:
1. Pregnant or lactating women
2. Those with any degree of ARI symptoms or fever.
3. Person with known history of severe hypersensitivity reaction to previous exposure to Ivermectin.
4. People with pre-existng severe medical conditions according to the judgement of
the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptomatic Covid-19 among the study participantsTimepoint: Between 7 and 10 days of Ivermectin intake
- Secondary Outcome Measures
Name Time Method Adverse effects of Ivermectin experienced by the study participantsTimepoint: On the day of Ivermectin intake and between 7 and 10 days of Ivermectin intake